🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to health experts.

An International Health Concern

The sexually transmitted infection are escalating worldwide, with figures suggesting in excess of 82 million infections per year. Especially elevated rates are observed in the African continent and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the face of growing infection rates, the spread of superbugs and the highly restricted available drugs presently on offer.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Gain Approval

Zoliflodacin, also known as a brand name, was cleared by the US FDA in mid-December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Scientists believe that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, created by the drugmaker GSK, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This authorization marks a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Outcomes and Worldwide Availability

According to data detailed in a major medical journal, the new drug cured the vast majority of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which involves an injection and a pill. The trial included hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have expressed optimism. Having a single-dose, oral treatment of this kind is described as a "critical tool" for public health efforts. This is considered vital to reduce the burden of the infection for people and to halt the transmission of untreatable gonorrhoea globally.